MCID: STR015
MIFTS: 39

Stereotypic Movement Disorder

Categories: Mental diseases

Aliases & Classifications for Stereotypic Movement Disorder

MalaCards integrated aliases for Stereotypic Movement Disorder:

Name: Stereotypic Movement Disorder 12 44 15 73
Stereotyped Repetitive Movements 12
Stereotypy Habit Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2303
ICD10 33 F98.4
ICD9CM 35 307.3
MeSH 44 D019956
SNOMED-CT 68 5507002
UMLS 73 C0038273

Summaries for Stereotypic Movement Disorder

Disease Ontology : 12 A specific developmental disorder that is characterized by repeated, rhythmic, purposeless movements or activities such as head banging, nail biting, or body rocking.

MalaCards based summary : Stereotypic Movement Disorder, also known as stereotyped repetitive movements, is related to trichotillomania and parasomnia, sleep bruxism type, and has symptoms including athetosis, clonus and muscular fasciculation. An important gene associated with Stereotypic Movement Disorder is PRL (Prolactin). The drugs Guanfacine and Methylphenidate have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and brain, and related phenotype is behavior/neurological.

Wikipedia : 76 Stereotypic movement disorder (SMD) is a motor disorder with onset in childhood involving repetitive,... more...

Related Diseases for Stereotypic Movement Disorder

Graphical network of the top 20 diseases related to Stereotypic Movement Disorder:



Diseases related to Stereotypic Movement Disorder

Symptoms & Phenotypes for Stereotypic Movement Disorder

UMLS symptoms related to Stereotypic Movement Disorder:


athetosis, clonus, muscular fasciculation, myoclonus, tremor, involuntary movements, recurrent muscle twitches (symptom)

MGI Mouse Phenotypes related to Stereotypic Movement Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.1 TAC1 CCK MECP2 NPY PRL SLITRK1

Drugs & Therapeutics for Stereotypic Movement Disorder

Drugs for Stereotypic Movement Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
2
Methylphenidate Approved, Investigational Phase 4,Phase 3 113-45-1 4158
3
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
4 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
5 Adrenergic Agents Phase 4,Phase 3,Phase 2
6 Adrenergic Agonists Phase 4
7 Adrenergic alpha-2 Receptor Agonists Phase 4
8 Adrenergic alpha-Agonists Phase 4
9 Antihypertensive Agents Phase 4
10 Anticonvulsants Phase 4,Not Applicable
11 Excitatory Amino Acid Antagonists Phase 4,Not Applicable
12 Excitatory Amino Acids Phase 4,Not Applicable
13 Neuroprotective Agents Phase 4
14 Protective Agents Phase 4,Phase 2
15
Sertraline Approved Phase 3,Phase 2 79617-96-2 68617
16
Aripiprazole Approved, Investigational Phase 3,Phase 2 129722-12-9 60795
17
Dopamine Approved Phase 3,Phase 2 51-61-6, 62-31-7 681
18
Acamprosate Approved, Investigational Phase 3,Phase 2 77337-76-9 71158
19
Ethanol Approved Phase 3,Phase 2 64-17-5 702
20 Brexpiprazole Approved, Investigational Phase 3 913611-97-9 11978813
21 Antidepressive Agents Phase 3,Phase 2
22 Neurotransmitter Uptake Inhibitors Phase 3,Phase 2
23 Psychotropic Drugs Phase 3,Phase 2,Not Applicable
24 Serotonin Agents Phase 3,Phase 2
25 Serotonin Uptake Inhibitors Phase 3,Phase 2
26 Antipsychotic Agents Phase 3,Phase 2
27 Central Nervous System Depressants Phase 3,Phase 2,Not Applicable
28 Tranquilizing Agents Phase 3,Phase 2,Not Applicable
29 Dopamine Agents Phase 3,Phase 2
30 Dopamine Antagonists Phase 3
31 Dopamine D2 Receptor Antagonists Phase 3
32 Paliperidone Palmitate Phase 3
33 Serotonin 5-HT2 Receptor Antagonists Phase 3
34 Serotonin Antagonists Phase 3
35 Atomoxetine Hydrochloride Phase 3
36 Central Nervous System Stimulants Phase 3
37 Dopamine Uptake Inhibitors Phase 3
38 Dopamine agonists Phase 3,Phase 2
39 Quetiapine Fumarate Phase 3 111974-72-2
40
Serotonin Investigational, Nutraceutical Phase 3,Phase 2 50-67-9 5202
41
Desipramine Approved, Investigational Phase 2 50-47-5 2995
42
Oxytocin Approved, Vet_approved Phase 2 50-56-6 439302 53477758
43
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
44
Citalopram Approved Phase 2 59729-33-8 2771
45
Zinc Approved, Investigational Phase 2 7440-66-6 23994
46
Bromocriptine Approved, Investigational Phase 2 25614-03-3 31101
47 Orange Approved, Nutraceutical Phase 2
48 Antidepressive Agents, Tricyclic Phase 2
49 Oxytocics Phase 2
50 Antidotes Phase 2

Interventional clinical trials:

(show top 50) (show all 78)
# Name Status NCT ID Phase Drugs
1 Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder Completed NCT01238575 Phase 4 extended-release guanfacine
2 Riluzole in Fragile X Syndrome Completed NCT00895752 Phase 4 Riluzole
3 Repetitive Behavior Disorders in People With Severe Mental Retardation Unknown status NCT00491478 Phase 3 sertraline
4 Study of Aripiprazole in the Treatment of Pervasive Developmental Disorders Completed NCT00870727 Phase 3 Aripiprazole oral product;Placebo oral capsule
5 Use of Acupuncture In Children With Autistic Spectrum Disorder Completed NCT00346736 Phase 3
6 Study of Paliperidone ER in Adolescents and Young Adults With Autism Completed NCT00549562 Phase 3 Paliperidone ER
7 Study of Aripiprazole in the Treatment of Serious Behavioral Problems in Children and Adolescents With Autistic Disorder (AD) Completed NCT00365859 Phase 3 Aripiprazole
8 Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism Completed NCT00498173 Phase 3 Atomoxetine;Placebo
9 A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms Completed NCT00541346 Phase 3 Methylphenidate Transdermal System
10 Acamprosate in Youth With Fragile X Syndrome Completed NCT01300923 Phase 3 Acamprosate
11 Brexpiprazole in Patients With Acute Schizophrenia Completed NCT01810380 Phase 3 Placebo;Brexpiprazole;Quetiapine extended release
12 Study of Acamprosate in Autism Recruiting NCT01813318 Phase 2, Phase 3 Acamprosate;Placebo
13 Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder Not yet recruiting NCT03487770 Phase 3 Aripiprazole Oral Solution;Placebo Oral Solution
14 Reducing Internalized Stigma in People With Serious Mental Illness Completed NCT01259427 Phase 2
15 Pilot Study of the Effects of the Desipramine on the Neurovegetative Parameters of the Child With Rett Syndrome Completed NCT00990691 Phase 2 Administration of a high dose of desipramine;Administration of a low dose of desipramine;Administration of a placebo
16 Short-term Behavioral Effects of Cholesterol Therapy in Smith-Lemli-Opitz Syndrome Completed NCT00114634 Phase 2
17 A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome Completed NCT00420459 Phase 2 Aripiprazole
18 Omega-3 Fatty Acids for Hyperactivity Treatment in Autism Spectrum Disorder Completed NCT01694667 Phase 2 Omega-3 Fatty Acids
19 Intranasal Oxytocin in the Treatment of Autism Completed NCT00490802 Phase 2 Oxytocin;Placebo
20 A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders Completed NCT00453180 Phase 2 N-acetylcysteine;Placebo
21 Citalopram for Children With Autism and Repetitive Behavior (STAART Study 1) Completed NCT00086645 Phase 2 citalopram hydrobromide
22 Intranasal Oxytocin Treatment for Social Deficits in Children With Autism Completed NCT01624194 Phase 2 Oxytocin nasal spray;Placebo
23 Treatment of Rett Syndrome With Recombinant Human IGF-1 Completed NCT01777542 Phase 2 Recombinant Human Insulin Growth Factor 1 (rhIGF-1);Placebo
24 Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder Recruiting NCT02909959 Phase 2 Sulforaphane;Placebo
25 Essential Oils for Enhancing QOL in ASD Recruiting NCT02543203 Phase 2
26 A 2-Period Crossover Study of BPN14770 in Adults Males With Fragile X Syndrome Recruiting NCT03569631 Phase 2 BPN14770;Placebo
27 Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis Suspended NCT00004300 Phase 2 bromocriptine;sertraline hydrochloride
28 Osteoconduction Potential of an Injectable Calcium Phosphate in Orthopaedic Surgery in Fillings of Osseous Defects Unknown status NCT00206791 Not Applicable
29 The Relationship Between Metamemory and Memory in Old Age Unknown status NCT02113345 Not Applicable
30 CORAL Study: Proof of Concept Trial Unknown status NCT01379014 Not Applicable
31 Cerebral Activity Related to Primary Motor Stereotypies in Children: An EEG Study. Completed NCT01037361
32 Use of Functional Behavioral Assessments to Evaluate Stereotypy and Repetitive Behaviors in a Double-blind, Placebo Controlled Trials of Various Medications Used to Treat Children With Autism. Completed NCT00211770
33 Ending Self Stigma for PTSD Completed NCT02734212 Not Applicable
34 A Pre and Post Test Intervention Design to Prevent Abortion and Contraceptive-use Stigma Among School Youths in Kenya Completed NCT03065842 Not Applicable
35 Use of a Visual Pedagogy and Structure With Children With Autism for Routine Physical Exams Completed NCT03232775 Not Applicable
36 An Intervention to Improve Communication Between Physicians and Minority Patients With Hypertension Completed NCT01037920 Not Applicable
37 Study Evaluating the Nasopharyngeal Carriage in Healthy Children Completed NCT00768833
38 Study of the Preliminary Effect of TEVAW: a Program to Address Intimate Partner Violence in Northern Tanzania Completed NCT02434796 Not Applicable
39 LINE: Treatment Patterns in postmenopausaL Women With Hormone Receptor Positive Breast Cancer Completed NCT01561443
40 Effectiveness of a Dissonance-Based Eating Disorder Prevention Program (The Body Project II) Completed NCT00663754 Not Applicable
41 Using the Prevent-Teach-Reinforce Model to Reduce Problem Behaviors in Children With Autism Spectrum Disorders Completed NCT02153203 Not Applicable
42 Comparative Evaluation of Gabapentine and Occlusal Splint in the Management of Sleep Bruxism Completed NCT01255878 Not Applicable Gabapentine
43 Identification and Research of Impacts of Social Categorization Process in Nurse Triage (SOCIAL SORTING) Completed NCT03379961
44 Eating Disorder Prevention Programs Completed NCT00042185 Not Applicable
45 Effects of Creatine Supplementation in Rett Syndrome Completed NCT01147575 Not Applicable
46 Evaluation of the Positive Prevention PLUS Program Completed NCT02540278 Not Applicable
47 Reducing Lesbian, Gay , Bisexual and Transgender (LGBT) Stigma in Swaziland and Lesotho Completed NCT02410434 Not Applicable
48 Dietary Fatty Acids Improve Social Impairment in Autism Spectrum Disorders Completed NCT01154894 Not Applicable
49 Impact of an Intensive Multimodal Educative Program on Behavioral Disorders of Patients With Profound Multiple Disabilities and on the Quality of Life and Feelings of Caregivers Completed NCT02510846 Not Applicable
50 Eating Disorders Programs: An Indicated Trial Completed NCT03259347 Not Applicable

Search NIH Clinical Center for Stereotypic Movement Disorder

Cochrane evidence based reviews: stereotypic movement disorder

Genetic Tests for Stereotypic Movement Disorder

Anatomical Context for Stereotypic Movement Disorder

MalaCards organs/tissues related to Stereotypic Movement Disorder:

41
Testes, Skin, Brain, Eye

Publications for Stereotypic Movement Disorder

Articles related to Stereotypic Movement Disorder:

(show all 14)
# Title Authors Year
1
GRIN1 mutations cause encephalopathy with infantile-onset epilepsy, and hyperkinetic and stereotyped movement disorders. ( 25864721 )
2015
2
Stereotypic movement disorder: a case for Procrustes? ( 25039962 )
2014
3
Cheek-biting disorder: another stereotypic movement disorder? ( 21889295 )
2011
4
Low dimensional temporal organization of spontaneous eye blinks in adults with developmental disabilities and stereotyped movement disorder. ( 19819672 )
2010
5
Trichotillomania (hair pulling disorder), skin picking disorder, and stereotypic movement disorder: toward DSM-V. ( 20533371 )
2010
6
Stereotypic movement disorder: easily missed. ( 20187883 )
2010
7
Escitalopram treatment of stereotypic movement disorder in an adolescent with mitochondrial disorder and mental retardation. ( 19519269 )
2009
8
Is trichotillomania a stereotypic movement disorder? An analysis of body-focused repetitive behaviors in people with hair-pulling. ( 19034750 )
2008
9
Trichotillomania, stereotypic movement disorder, and related disorders. ( 17880861 )
2007
10
Opiate sensitivity test in patients with stereotypic movement disorder and trichotillomania. ( 12369265 )
2002
11
Stereotypic movement disorder after acquired brain injury. ( 12097226 )
2002
12
Characteristics of stereotypic movement disorder and self-injurious behavior assessed with the Diagnostic Assessment for the Severely Handicapped (DASH-II). ( 9403928 )
1997
13
Stereotypic movement disorder. ( 9164434 )
1997
14
DSM-IV stereotypic movement disorder: persistence of stereotypies of infancy in intellectually normal adolescents and adults. ( 8617696 )
1996

Variations for Stereotypic Movement Disorder

Expression for Stereotypic Movement Disorder

Search GEO for disease gene expression data for Stereotypic Movement Disorder.

Pathways for Stereotypic Movement Disorder

GO Terms for Stereotypic Movement Disorder

Cellular components related to Stereotypic Movement Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.35 CCK NPY PRL SLITRK1 TAC1
2 extracellular space GO:0005615 9.1 CCK MECP2 NPY PRL SLITRK1 TAC1

Biological processes related to Stereotypic Movement Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.65 CCK MECP2 PRL
2 regulation of signaling receptor activity GO:0010469 9.61 CCK NPY PRL
3 neuropeptide signaling pathway GO:0007218 9.46 NPY TAC1
4 regulation of blood pressure GO:0008217 9.4 NPY TAC1
5 synapse assembly GO:0007416 9.37 MECP2 SLITRK1
6 chemical synaptic transmission GO:0007268 9.33 MECP2 NPY TAC1
7 positive regulation of synapse assembly GO:0051965 9.32 MECP2 SLITRK1
8 sensory perception of pain GO:0019233 9.26 MECP2 TAC1
9 long-term memory GO:0007616 8.96 MECP2 TAC1
10 behavioral fear response GO:0001662 8.62 CCK MECP2

Molecular functions related to Stereotypic Movement Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 8.96 CCK NPY
2 hormone activity GO:0005179 8.8 CCK NPY PRL

Sources for Stereotypic Movement Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....